SCHEMBL104445

SCHEMBL104445

C1CCC2CCCC[C]2C1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316141 1.00 CA1 (0.33) CA1CA2CA4KMT2A
SCHEMBL13858690 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL1849298 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL61394 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL7340365 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL25327994 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL11594630 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL542776 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL7992221 0.97 KMT2A (0.36) CA1CA2CA4KMT2A
SCHEMBL9956415 0.97 KMT2A (0.36) CA1CA2CA4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1967 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166645-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2024-05-23 US claimed
EP-4289843-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2023-12-13 EP claimed
US-20210246264-A1 METHOD OF MAKING MIXTURE OF POLYMERS SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2021-08-12 US claimed
EP-3810676-A1 METHOD OF MAKING MIXTURE OF POLYMERS Solvay Specialty Polymers Italy S.p.A. (IT) 2021-04-28 EP claimed
WO-2019243404-A1 METHOD OF MAKING MIXTURE OF POLYMERS SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2019-12-26 WO claimed
EP-3013802-B1 N-CYCLOALKYL-N-[(BICYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2019-08-14 EP claimed
US-9770022-B2 N-cycloalkyl-N-[(bicyclylphenyl)methylene]-(thio)carboxamide derivatives BAYER CROPSCIENCE AG (DE) 2017-09-26 US claimed
US-20160150777-A1 N-CYCLOALKYL-N-[(BICYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2016-06-02 US claimed
EP-3013802-A1 N-CYCLOALKYL-N-[(BICYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES Bayer Cropscience AG (DE) 2016-05-04 EP claimed
WO-2014206953-A1 N-CYCLOALKYL-N-[(BICYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2014-12-31 WO claimed
US-6100271-A Therapeutic compounds containing xanthinyl CELL THERAPEUTICS, INC. (US) 2000-08-08 US claimed
US-6043250-A Methods for using therapeutic compounds containing xanthinyl CELL THERAPEUTICS, INC. (US) 2000-03-28 US claimed
EP-0934302-A2 AMINOPHENOL DERIVATES BAYER AG (DE) 1999-08-11 EP claimed
WO-1998016522-A2 AMINOPHENOL DERIVATES WITH FUNGICIDAL PROPERTY BAYER AKTIENGESELLSCHAFT (DE) 1998-04-23 WO claimed
EP-0746557-A4 INTRACELLULAR SIGNALLING MEDIATORS CELL THERAPEUTICS INC (US) 1997-05-02 EP claimed
EP-0746557-A1 INTRACELLULAR SIGNALLING MEDIATORS CELL THERAPEUTICS, INC. (US) 1996-12-11 EP claimed
WO-1995022546-A1 INTRACELLULAR SIGNALLING MEDIATORS CELL THERAPEUTICS, INC. (US) 1995-08-24 WO claimed
WO-1995020589-A1 CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 1995-08-03 WO claimed
EP-0549391-A1 Ophthalmic lenses based on polyurethanes derived from polythiols ESSILOR INTERNATIONAL, Compagnie Générale d'Optique (FR) 1993-06-30 EP claimed
US-4472383-A HYPOTENSIVE AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1984-09-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166645-A1 PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF SOS1, WEE1, SOS2 CA1 3433/4885CA2 3015/4885CA4 2936/4885
US-20160150777-A1 N-CYCLOALKYL-N-[(BICYCLYLPHENYL)METHYLENE]-(THIO)CARBOXAMIDE DERIVATIVES CBR3, CYCS, CBR1 CA1 3757/4885CA2 1876/4885CA4 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.